Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Apogee Therapeutics, Inc. (NASDAQ: APGE) announced on May 27, 2026, a strategic financing collaboration with Blackstone Life Sciences designed to secure up to $1.3 billion in flexible, non-dilutive capital for the development and potential commercialization of its lead drug candidate, zumilokibart. The transaction combines approximately...